[Evaluation of response to treatment in chronic hepatitis C].
Département d'Hépato-Gastroentérologie, Centre Hospitalo-Universitaire.
Vincent
V
Leroy
Marie-Noëlle
MN
Hilleret
D000410:Alanine Transaminase / Q000097:blood; D000547:Amantadine / Q000008:administration & dosage / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001706:Biopsy; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000209:etiology; D004796:Clinical Enzyme Tests; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000821:virology*; D006801:Humans; D015994:Incidence; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000453:epidemiology / Q000209:etiology; D015201:Meta-Analysis as Topic; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D013997:Time Factors; D000637:Transaminases / Q000097:blood; D014766:Viremia / Q000175:diagnosis*
D000998:Antiviral Agents; D012367:RNA, Viral; D012254:Ribavirin; D007372:Interferons; D000547:Amantadine; D000637:Transaminases; D000410:Alanine Transaminase